Clubhouse Drop-in audio chat app logo on the App Store is seen displayed on a phone screen in this illustration photo taken in Poland on February 3, 2021.  (Photo illustration by Jakub Porzycki/NurPhoto via Getty Images)
Cover Clubhouse, the drop-in audio chat app is taking the world by storm, but co-founder Rohan Seth is hard at work on another project— Lydian Accelerator. (Photo courtesy of Getty Images).

As well as launching an app hailed as the next big thing in social media, Rohan Seth is also building Lydian Accelerator, a non-profit group for genetic treatment, inspired by his daughter.

The new social media app Clubhouse has dominated conversation since the start of this year for its exciting possibilities for connecting to others in the pandemic era. After securing a US$100 million investment in January and finding a fan in Elon Musk, the live audio, invite-only app is a hot commodity right now and has made tech industry stars of its founders Rohan Seth and Paul Davison. Although the two are quite press shy, Seth has been hard at work on another project close to his heart that he wants everyone to know about: an accelerator program to customise genetic treatments for children born with severe gene mutations.

When Seth and his wife Jennifer welcomed their daughter Lydia in early 2019, they couldn’t have predicted the hardship that would follow. Born with a mutated gene named KCNQ2, which affects brain function, Lydia started having seizures from birth. She was classed as “severely disabled” by doctors and subsequently was unable to progress “beyond a few months of age without ever having the ability to crawl, walk or talk,” says Seth.

The Stanford University graduate founded Lydian Accelerator, a non-profit group named after Lydia later that year, to create custom genetics treatments for his daughter and others like her, while routinely chronicling the journey on his website, in the hope that his research would shed light on how common genetic mutations are.

Through extensive research and conversations with leading scientists, the couple discovered a technology called antisense oligonucleotides (ASO) which can combat the mutation in its infant stages, giving their daughter and others like her a chance of recovery. Though the ASO technology would need to be customised for every patient, which would take months of research, the couple decided to tackle this problem the only way they knew how—as computer scientists—by open-sourcing their daughter’s treatment and making it available to all, providing others with the tools to advocate for their childs’ health too.

See also: Here's What You Need to Know About Clubhouse, and Why You Should Join